The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Phase II Study of Imatinib in Advanced Chordoma
Abstract
Purpose: To explore the antitumor activity of imatinib in patients with advanced platelet-derived growth factor β (PDGFB)/PDGF receptor β (PDGFRB)–positive chordomas. Patients and Methods: In a collaborative Italian-Swiss, prospective, phase II clinical study conducted from November 2004 through April 2006, 56 patients with advanced PDGFB and/or PDGFRB chordoma received 800 mg/d of imatinib until progression. The primary end point was the overall tumor response rate (ORR), defined by RECIST. Secondary, exploratory end points included tissue response (ie, changes in tumor density or signal intensity/contrast enhancement, and/or [18F]-fluorodeoxyglucose positron emission tomography [PET] uptake), overall survival, progression-free survival (PFS), and pain score. Results: Among 50 patients evaluable by RECIST, the best response was one partial response (PR) obtained at 6 months (ORR, 2%). There were 35 patients with stable disease (SD, 70%) and a 64% clinical benefit rate (ie, RECIST complete response + PR + SD ≥ 6 months). A minor dimensional response (< 20%) was detected in nine patients. A maximum standard uptake value decrease ≥ 25% was observed in 10 (39%) of 26 patients evaluable for PET response at 3 months. Changes in the Brief Pain Inventory score were consistent with the response assessment. Median PFS (intention-to-treat population, 56 patients) was 9 months. No unexpected toxicities were observed. Conclusion: This is the largest phase II study in chordoma to date. It confirms anecdotal evidence that imatinib has antitumor activity in this orphan disease, and therefore, it is worth further investigation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Measurement of Observer Agreement for Categorical Data
Landis, J. R., & Koch, G. G. (1977) · Biometrics · doi:10.2307/2529310 · Cited by 81,148
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_25 · Cited by 45,181
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1958) · Journal of the American Statistical Association · doi:10.1080/01621459.1958.10501452 · Cited by 39,158
New Guidelines to Evaluate the Response to Treatment in Solid Tumors
Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian, M. C., et al. (2000) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/92.3.205 · Cited by 15,660
Pain assessment: global use of the Brief Pain Inventory.
Cs, C., & Km, R. (1994) · PubMed · Cited by 5,421
Young, H., Baum, R., Cremerius, U., Herholz, K., Hoekstra, O., Lammertsma, A. A., Pruim, J., & Price, P. (1999) · European Journal of Cancer · doi:10.1016/s0959-8049(99)00229-4 · Cited by 1,720
Choi, H., Charnsangavej, C., Faria, S. C., Macapinlac, H. A., Burgess, M. A., Patel, S. R., Chen, L. L., Podoloff, D. A., & Benjamin, R. S. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.07.3049 · Cited by 1,520
Blanke, C. D., Rankin, C., Demetri, G. D., Ryan, C. W., von Mehren, M., Benjamin, R. S., Raymond, A. K., Bramwell, V. H. C., Baker, L. H., Maki, R. G., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.13.4452 · Cited by 1,073
Proton radiation therapy for chordomas and chondrosarcomas of the skull base
Hug, E. B., Loredo, L. N., Slater, J. D., Devries, A., Grove, R. I., Schaefer, R. A., Rosenberg, A. E., & Slater, J. M. (1999) · Journal of Neurosurgery · doi:10.3171/jns.1999.91.3.0432 · Cited by 510
Gastrointestinal Stromal Tumor Meta-Analysis Group (MetaGIST) (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.24.2099 · Cited by 479
Chordoma of the Mobile Spine: Fifty Years of Experience
Boriani, S., Bandiera, S., Biagini, R., Bacchini, P., Boriani, L., Cappuccio, M., Chevalley, F., Gasbarrini, A., Picci, P., & Weinstein, J. N. (2006) · Spine · doi:10.1097/01.brs.0000200038.30869.27 · Cited by 425
Van Glabbeke, M. M., Owzar, K., Rankin, C., Simes, J., Crowley, J., & GIST Meta-analysis Group (MetaGIST) (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.25.18_suppl.10004 · Cited by 385
George, S., Merriam, P., Maki, R. G., Van den Abbeele, A. D., Yap, J. T., Akhurst, T., Harmon, D. C., Bhuchar, G., O'Mara, M. M., D'Adamo, D. R., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.20.9890 · Cited by 321
Ares, C., Hug, E. B., Lomax, A. J., Bolsi, A., Timmermann, B., Rutz, H. P., Schuller, J. C., Pedroni, E., & Goitein, G. (2009) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2008.12.055 · Cited by 279
Casali, P. G., Messina, A., Stacchiotti, S., Tamborini, E., Crippa, F., Gronchi, A., Orlandi, R., Ripamonti, C., Spreafico, C., Bertieri, R., et al. (2004) · Cancer · doi:10.1002/cncr.20618 · Cited by 268
Self-citationPhase II Study of High-Dose Photon/Proton Radiotherapy in the Management of Spine Sarcomas
DeLaney, T. F., Liebsch, N. J., Pedlow, F. X., Adams, J., Dean, S., Yeap, B. Y., McManus, P., Rosenberg, A. E., Nielsen, G. P., Harmon, D. C., et al. (2009) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2008.08.058 · Cited by 264
Response to imatinib plus sirolimus in advanced chordoma
Stacchiotti, S., Marrari, A., Tamborini, E., Palassini, E., Virdis, E., Messina, A., Crippa, F., Morosi, C., Gronchi, A., Pilotti, S., et al. (2009) · Annals of Oncology · doi:10.1093/annonc/mdp210 · Cited by 173
Self-citationTamborini, E., Miselli, F., Negri, T., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1584 · Cited by 148
Self-citationResponse to Sunitinib Malate in Advanced Alveolar Soft Part Sarcoma
Stacchiotti, S., Tamborini, E., Marrari, A., Brich, S., Rota, S. A., Orsenigo, M., Crippa, F., Morosi, C., Gronchi, A., Pierotti, M. A., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-2050 · Cited by 145
Self-citationEffectiveness of Cetuximab/Gefitinib in the Therapy of a Sacral Chordoma
Hof, H., Welzel, T., & Debus, J. (2006) · Oncology Research and Treatment · doi:10.1159/000096283 · Cited by 131
Shalaby, A., Presneau, N., Ye, H., Halai, D., Berisha, F., Idowu, B. D., Leithner, A., Liegl, B., Briggs, T. W. R., Bácsi, K., et al. (2010) · The Journal of Pathology · doi:10.1002/path.2818 · Cited by 118
Demetri, G. D., & ELIAS, A. D. (1995) · Hematology/Oncology Clinics of North America · doi:10.1016/s0889-8588(18)30070-4 · Cited by 115
Basciani, S., Mariani, S., Arizzi, M., Ulisse, S., Rucci, N., Jannini, E. A., Rocca, C. D., Manicone, A. M., Carani, C., Spera, G., et al. (2002) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.87.5.8476 · Cited by 112
Analysis of receptor tyrosine kinases (RTKs) and downstream pathways in chordomas
Tamborini, E., Virdis, E., Negri, T., Orsenigo, M., Brich, S., Conca, E., Gronchi, A., Stacchiotti, S., Manenti, G., Casali, P. G., et al. (2010) · Neuro-Oncology · doi:10.1093/neuonc/noq003 · Cited by 101
Self-citationDemetri, G. D., & ELIAS, A. D. (1995) · PubMed · Cited by 97
Phase II Study of 9-Nitro-Camptothecin in Patients With Advanced Chordoma or Soft Tissue Sarcoma
Chugh, R. K., Dunn, R. L., Zalupski, M. M., Biermann, J. S., Sondak, V. K., Mace, J. R., Leu, K. M., Chandler, W. F., & Baker, L. H. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.02.170 · Cited by 95
Lindén, O., Stenberg, L., & Kjellén, E. (2008) · Acta Oncologica · doi:10.1080/02841860802266672 · Cited by 68
Han, S., Polizzano, C., Nielsen, G. P., Hornicek, F. J., Rosenberg, A. E., & Ramesh, V. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-2364 · Cited by 60
Long term survivors of childhood brain cancer have an increased risk for cardiovascular disease
(2000) · Pure Amsterdam UMC · doi:10.1002/(sici)1097-0142(20000501)88:9
Cited by
Descriptive epidemiology of sarcomas in Europe: Report from the RARECARE project
Stiller, C. A., Trama, A., Serraino, D., Rossi, S., Navarro, C., Chirlaque, M. D., & Casali, P. G. (2013) · European Journal of Cancer · doi:10.1016/j.ejca.2012.09.011 · Cited by 683
Self-citationCasali, P. G., Bielack, S., Abecassis, N., Aro, H. T., Bauer, S., Biagini, R., Bonvalot, S., Boukovinas, I., Bovee, J. V. M. G., Brennan, B., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy310 · Cited by 617
Self-citationTargeting the PDGF signaling pathway in tumor treatment
Heldin, C.-H. (2013) · Cell Communication and Signaling · doi:10.1186/1478-811x-11-97 · Cited by 540
Stacchiotti, S., & Sommer, J. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(14)71190-8 · Cited by 501
Self-citationImatinib: A Breakthrough of Targeted Therapy in Cancer
Iqbal, N., & Iqbal, N. (2014) · Chemotherapy Research and Practice · doi:10.1155/2014/357027 · Cited by 470
Metadata
- Authors
- Stacchiotti, S., Longhi, A., Ferraresi, V., Grignani, G., Comandone, A., Stupp, R., Bertuzzi, A., Tamborini, E., Pilotti, S., Messina, A., Spreafico, C., Gronchi, A., Amore, P., Vinaccia, V., & Casali, P. G.
- Venue
- Journal of Clinical Oncology
- Published
- 2012-03-20
- Volume
- 30
- Issue
- 9
- Pages
- 914-920
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W1988995169
- Cited by
- 276
- References
- 29
- FWCI
- 14.59
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.